

Professor Richard Eastell
Clinical Sciences Centre (North)
Northern General Hospital
Herries Road,
SHEFFIELD
S5 7AU

Our ref: SM/DO
Your ref:
Date: 25th May 2005

Dear Professor Eastell,

We are instructed by Dr Aubrey Blumsohn.

You will be aware that our client has serious concerns and questions relating to studies carried out in Sheffield regarding pharmaceutical clinical trials involving the drug Risedronate. He has instructed us to request that you to send all raw data relating to three scientific abstracts published in his name relating to this drug. Two of these abstracts are:

1. Relative Contributions Of The Early Changes In Bone Resorption And Later Changes In Hip Bone Mineral Density To The Reduction In Vertebral Fracture Risk With Risedronate. A. Blumsohn, IP Barton, A Chines, R Eastell. American Society for Bone and Mineral Research, 2003
2. Relationship Of Early Changes In Bone Turnover To The Reduction In Vertebral Fracture Risk With Risedronate - The HIP Study. A. Blumsohn, IP Barton, A Chines, R Eastell. American Society for Bone and Mineral Research, 2003

The third abstract contains identical information. Further my client requests that you make available to him all raw data relating to the following published scientific paper relating to the drug Risedronate:

Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18(6):1051-1056

You will be aware that the data underlying the information presented in this paper forms a subset of the data underlying the two abstract presentations published in our client's name. Our client wishes to compare data obtained with other information and data in his possession. He believes that the scientific process leading to these publications was improper. Further, he believes that the presentation of information in all these publications was false.

Our client has requested this data previously. We would appreciate it if you would send the raw and full data in electronic form to the writer's email address, simon.mckay@mckaylaw.co.uk within the next seven days. Data should include all variables required to reconstruct the analyses referred to in these publications, as well as the information pertaining to therapeutic adherence within the studies as requested by our client previously.

Data should be sent on a read-only CD-Rom, properly labelled and signed. If you wish, data may be sent in a password encoded file, and you may transfer the password to our client separately.

Yours sincerely

McKAY LAW

6-7 Park Place
Leeds
LS1 2RU
www.rlb-law.com
Direct Dial +44 (0)113 261 5515

Tel +44 (0)113 234 1220
Fax +44 (0)113 234 1573
DX 14086 Leeds Park Square
info@rlb-law.com
kate.williams@rlb-law.com

COPY LETTER

RadcliffesLeBrasseur

Messrs McKay Law
Solicitors
41 St Paul's Street
LEEDS
LS1 2JG

9 June 2005

Our Ref: CJW2/MD/900100.8703

Your Ref: SM DO

L 250363 v1

Dear Sirs

Re: Our Clients - Professor R Eastell

We act for the Medical Protection Society on behalf of its member Professor Eastell. We have been passed a copy of your letter to Professor Eastell dated 25th May, asking for certain raw data underlying certain abstracts, which you identify.

As you say, your client has asked for this information before. But it is not information to which Professor Eastell has access. It belongs to the pharmaceutical companies. As your client knows, Professor Eastell has already requested the data from the Pharmaceutical companies. (Professor Eastell explained this in a letter to your client dated 13th December 2004, a copy of which is enclosed). Therefore Professor Eastell regrets that he is unable to help.

Yours faithfully,

RadcliffesLeBrasseur

COPY

